{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+XR+%28Envarsus%29&page=2",
    "query": {
      "intervention": "Tacrolimus XR (Envarsus)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+XR+%28Envarsus%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+XR+%28Envarsus%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T17:51:20.590Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03437577",
      "title": "Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant Failure and Rejection"
      ],
      "interventions": [
        {
          "name": "immediate-release tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "extended release tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-05-08",
      "completion_date": "2020-03-31",
      "has_results": true,
      "last_update_posted_date": "2021-04-15",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03437577"
    },
    {
      "nct_id": "NCT03828682",
      "title": "Veloxis de Novo Kidney Transplant ECSWD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Immunosuppression"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolic Acid Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Simon Tremblay, PharmD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2019-06-21",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-05-13",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03828682"
    },
    {
      "nct_id": "NCT02339246",
      "title": "Pharmacokinetic Comparison Of All FK-506 Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "Prograf vs Envarsus XR vs Astagraf XL",
          "type": "DRUG"
        },
        {
          "name": "Prograf vs Astagraf XL vs Envarsus XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-01",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-01-18",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339246"
    },
    {
      "nct_id": "NCT03270462",
      "title": "CNS Study of Patients Switching From Tacrolimus to Envarsus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplant Patients"
      ],
      "interventions": [
        {
          "name": "Envarsus XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-12-01",
      "completion_date": "2020-06-02",
      "has_results": true,
      "last_update_posted_date": "2022-06-02",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03270462"
    },
    {
      "nct_id": "NCT03511560",
      "title": "Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplant Rejection",
        "Kidney Transplant Failure and Rejection"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Extended Release Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2018-07-26",
      "completion_date": "2021-07-17",
      "has_results": true,
      "last_update_posted_date": "2024-07-17",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03511560"
    },
    {
      "nct_id": "NCT03769298",
      "title": "CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Kidney Pancreas Transplantation"
      ],
      "interventions": [
        {
          "name": "Envarsus XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-02-27",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03769298"
    },
    {
      "nct_id": "NCT03410654",
      "title": "Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Kidney Transplant; Complications"
      ],
      "interventions": [
        {
          "name": "Tacrolimus, Extended Release, (Envarsus Xr)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2018-10-24",
      "completion_date": "2024-07-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03410654"
    },
    {
      "nct_id": "NCT03380936",
      "title": "Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]",
          "type": "DRUG"
        },
        {
          "name": "Plasma Exchange and IVIG (Intravenous Immunoglobulin )",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-01-17",
      "completion_date": "2019-10-16",
      "has_results": false,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380936"
    },
    {
      "nct_id": "NCT03321656",
      "title": "Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Envarsus XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roberto Gedaly",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 78,
      "start_date": "2019-03-28",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03321656"
    },
    {
      "nct_id": "NCT03680092",
      "title": "Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "GVHD",
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "abatacept",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dimitrios Tzachanis, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2019-11-26",
      "completion_date": "2023-06-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-10-09T17:51:20.590Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03680092"
    }
  ]
}